Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04768881 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04768881 is a Phase 2 study that was terminated before completion, run by Karyopharm Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT04768881, a Phase 2 study, was terminated before completion, sponsored by Karyopharm Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI therapy in Arm B. Participants who have disease progression (PD) after discontinuation of CPIs, especially in neoadjuvant or adjuvant therapy, will be considered to have acquired resistance in this study. Participants will receive study treatment (Selinexor and Pembrolizumab) until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.
Interventions
- DRUG Pembrolizumab
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04768881
The ClinicalTrials.gov registry entry for NCT04768881 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04768881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04768881 about?
NCT04768881 is a clinical study titled "Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma". Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI therapy in Arm B. Participants...
What is the current status of trial NCT04768881?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-05-12. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT04768881?
The interventions under investigation include: Pembrolizumab (DRUG), Selinexor (DRUG).
Who is sponsoring clinical trial NCT04768881?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.